Showing 3521-3530 of 18631 results for "".
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
https://reachmd.com/programs/cme/recent-updates-on-ovarian-function-suppression-in-premenopausal-hr-early-stage-breast-cancer/32906/Optimize ovarian function suppression in HR+ early-stage breast cancer with expert insights on timing and duration to enhance patient outcomes.Case Management Strategies for Patients with ADPKD – Part 2
https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-2/13880/This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in tFactoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF
https://reachmd.com/programs/cme/factoring-solutions-to-the-management-of-stroke-care-in-the-settings-of-secondary-prevention-and-af/29099/Hear the experts discuss the potential of anticoagulation therapies on the prevention of ischemic stroke and secondary stroke in patients with AF.Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
https://reachmd.com/programs/cme/mechanism-driven-gmg-therapy-fcrn-antagonists-and-the-rise-of-precision-neurology/36277/Review FcRn antagonists in gMG, including mechanisms, pivotal trials, and strategies for integrating novel therapies into personalized care.New and Emerging PAH Therapies and Approaches: A Mixture of Hope and Complexity
https://reachmd.com/programs/cme/new-and-emerging-pah-therapies-and-approaches-a-mixture-of-hope-and-complexity/36095/There are new and emerging therapies for PAH. Hear our experts discuss treatment approaches and why making the right diagnosis is key for selecting and individualizing therapy.Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
https://reachmd.com/programs/project-oncology/stratifying-advanced-endometrial-cancer-real-world-outcomes-by-molecular-subtype/35509/A recent study published in the International Journal of Gynecological Cancer found that molecular subtype was a significant predictor of time-to-recurrence and cancer-specific survival in advanced endometrial cancer. Dive into the data and explore implications for tailoring patient care.Prognostic Tools in the Management of ADPKD
https://reachmd.com/programs/cme/prognostic-tools-in-the-management-of-adpkd/13877/This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD. This activity is not available for continuing educManagement of ADPKD
https://reachmd.com/programs/cme/management-of-adpkd/13878/This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD. This activity is not available for continuing education credit.Elevating CKD-aP Care: New Frontier
https://reachmd.com/programs/cme/elevating-ckd-ap-care-new-frontier/36298/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
https://reachmd.com/programs/cme/primary-care-for-the-brain-prevention-and-early-detection-of-cognitive-decline/39897/In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a t